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Abstract
Background: Glioma is the most aggressive tumor of the brain and the most efficient treatments are based on radiotherapy.
However, tumors are often resistant to radiotherapy due to an enhanced DNA repair activity. Short and stabilized DNA
molecules (Dbait) have recently been proposed as an efficient strategy to inhibit DNA repair in tumor.
Methodology/Principal Findings: The distribution of three formulations of Dbait, (i) Dbait alone, (ii) Dbait associated with
polyethylenimine, and (iii) Dbait linked with cholesterol (coDbait), was evaluated one day after intratumoral delivery in an
RG2 rat glioma model. Dbait molecule distribution was assessed in the whole organ with 2D-FRI and in brain sections.
CoDbait was chosen for further studies given its good retention in the brain, cellular localization, and efficacy in inducing
the activation of DNA repair effectors. The radiosensitizing effect of coDbait was studied in four groups of rats bearing RG2-
glioma: no treatment, radiotherapy only, coDbait alone, and CoDbait with radiotherapy. Treatment started 7 days after
tumor inoculation and consisted of two series of treatment in two weeks: coDbait injection followed by a selective 6-Gy
irradiation of the head. We evaluated the radiosensitizing effect using animal survival, tumor volume, cell proliferation, and
vasculature characteristics with multiparametric MRI. CoDbait with radiotherapy improved the survival of rats bearing RG2-
glioma by reducing tumor growth and cell proliferation without altering tumor vasculature.
Conclusion/Significance: coDbait is therefore a promising molecular therapy to sensitize glioma to radiotherapy.
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Introduction
Among all the tools available to clinicians, radiotherapy-based
treatments are currently the leading strategy used to improve the
clinical outcome in glioma patients [1]. However, several
limitations are often encountered after irradiation, such as necrosis
in normal brain tissue and, importantly, the capability of tumor
cells to develop molecular mechanisms leading to radioresistance
[2].
One approach to improve patients’ outcome is to combine the
beneficial effect of radiotherapy (RT) with the effects of already
clinically approved therapies, such as antiangiogenic, vascular
disruptive agents, and cytotoxic agents [3–5]. Another emerging
strategy is to directly target the mechanisms that are involved in
radioresistance [2]. Given that irradiation directly damages DNA,
mainly in the form of single- or double-strand breaks (DSB) [6],
several molecules are currently in preclinical or clinical trials and
aim at inhibiting proteins that are involved in one of the DNA
repair pathways [7,8]. However, to date, none of these molecular
therapies has proved to be successful. Here we have tested a new
strategy for inhibiting the DSB repair pathway called Dbait in
association with RT for treating glioblastoma in an orthotopic
animal model.
Dbait molecules are short double-strand DNA that mimic DSB
and are recognized as damaged by repair and signaling proteins.
As a consequence, they trigger a ‘‘false’’ signaling of DNA damage
and inhibit repair of the damage induced by irradiation in treated
cells [9]. This approach has already given promising results in
radiosensitizing several types of tumors in vitro and in vivo in
subcutaneous xenograft models [10,11]. The preclinical studies on
skin melanoma indicate that Dbait is well tolerated and does not
increase radiotoxicity on healthy skin. These results led us to start
a phase I clinical trial to assess the tolerance and efficacy of Dbait
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combined with RT on patients with melanoma in transit
(#NCT01469455, registered on http://clinicaltrials.gov).
The Dbait strategy has not been evaluated in an orthotopic
model of glioma. Since irradiation-induced central nervous system
neurotoxicity is a major problem in developing new therapeutic
approaches for treating glioblastoma, it is important to assess its
safety and efficacy on animals using Dbait to improve RT in brain
tissue. Dbait molecules do not spontaneously enter cells of
subcutaneous tumors [11]. Several publications have described
efficient cellular uptake in mouse brain of naked DNA [12] or
DNA combined with PAMAM dendrimer conjugates [13–15],
lipids [16,17], or polyethylenimine [16,18]. Dbait molecules were
previously administered in subcutaneous tumors after complexion
with polyethylenimine (PEI), which increases intracellular delivery
[10]. However, the range of Dbait concentrations achievable in
association with PEI remains limited for in vivo purposes. This
limitation can be overcome using cholesterol as a transfection
agent. This approach has already shown efficiency for in vivo
delivery of siRNA in the central nervous system [19], and recently
of Dbait molecules in zebrafish early embryos and in mouse
xenografted tumors [11].
Here, we first studied the distribution of various Dbait
formulations after injection into healthy striatum or into tumor
tissue in the RG2 orthotopic rat model of glioma. We then
assessed the safety of cholesterol-coupled Dbait (coDbait) injection
with RT in normal rat brain. The radiosensitizing effect of
coDbait was finally addressed by evaluating the survival of rats
bearing RG2-glioma and by analyzing tumor growth and
microvasculature with multiparametric MRI [20,21].
Methods
Ethic Statement
All animal experiments were conducted under permits
no. 380820 and no. A3851610008 from the French Ministry of
Agriculture. The protocols were approved by the local committee
for animal care and use of the Grenoble Institute of Neuroscience
(Comite´ d’e´thique pour l’expe´rimentation animale, GIN, amend-
ed by the Comite´ National de Re´flexion Ethique sur l’Expe´ri-
emtation Animale). All surgery was performed under isoflurane
anesthesia with additional local analgesia, and all efforts were
made to minimize suffering.
Animal Model
The RG2 cells (ATCC, CRL-223) were implanted in the
brain of male Fisher 344 rats (150–200 g, Charles River,
France) with a stereotactic frame as previously described [22].
Tumor cells were inoculated under anesthesia with the following
parameters: 5% isoflurane for induction and 2.5% for mainte-
nance in 100% air. Bupivacaine (8 mg/kg) was injected
subcutaneously before incision to prevent postoperative pain.
RG2 cells (5 103) in 5 mL serum-free alpha-MEM medium were
inoculated at 5 mL/min in the right caudate nucleus through a
1-mm burr hole with the following coordinate from Bregma:
AP=0, ML=3.5, DV=5.5 mm. After injection, the burr hole
was filled with bone wax, the skin incision was sewed and the
animals were observed until awakening prior to being returned
to the animal facility.
Treatments
Dbait molecules. Dbait32Hc (molecular mass, 20.153 kDa)
molecules were obtained by automated solid-phase oligonucleotide
synthesis from Eurogentec (Seraing, Belgium). Three formulations
of Dbait were used: Dbait32Hc alone (Dbait), Dbait32Hc in a
mixture with in vivo-jet polyethylenimine reagent (PEI; Polyplus
Transfection) (Dbait/PEI) as previously described [10], and
Dbait32Hc coupled with a molecule of cholesterol (coDbait). For
the distribution analysis, Dbait molecules were additionally
coupled with the near infra-red (NIR) cyanine-5.5 dye. All Dbait
formulations were diluted in a solution of 5% glucose.
Dbait formulation delivery and quantities. Intracranial
and intratumoral injections were made by convection enhanced
delivery (CED). This procedure consists of an injection at a limited
rate (0.5 mL/min) of 10 mL for a duration of 20 min. The CED
procedure ensures a homogenous deposit of a high amount of
molecules into the targeted tissue. Animals were placed in a
stereotactic frame and the operation was performed as described
above. For distribution studies, the quantities of Dbait molecules
were the following: Dbait alone and coDbait: 100 mg, Dbait/PEI:
10 mg. The quantity of Dbait/PEI used was the maximum
achievable quantity of the Dbait molecule and dictated by Dbait
solubility in the PEI solution. Two injections of coDbait, 100 mg
each, were made to assess the radiotherapeutic protocol in non
tumoral rat brain. At the same time, the brain tolerance study was
conducted using two quantities of coDbait: 200 and 500 mg. The
radiosensitizing effect was evaluated on tumoral brain with two
injections of coDbait, 400 mg each.
Chloroquine injection. Chloroquine was used for its ability
to promote entry of DNA molecules into the cell cytoplasm via
increased endocytosis [23]. Chloroquine (Sigma) was prepared at
10 mg/ml in saline solution and was used either freshly or after
storage at 4uC for up to 2 days. Chloroquine (10 mg/kg) was
administered with 2 intraperitoneal (ip) injections 1 day and at
least 3 hours prior to the administration of Dbait molecules.
Irradiation. Isoflurane-anesthetized rats received gamma
irradiation (60Co, source ICO 4000) [24] at a dose rate of
0.50 Gy/min. The source of irradiation was collimated in order to
specifically target the animals’ head. Control rats were anesthe-
tized but were not exposed to the radiation source.
Dbait Quantification
Brain samples were weighed and homogenized with lysis
buffer (guanidium hydrochloride, sodium acetate, lauroylsarco-
sine; 5 mL of lysis buffer per gram of tissue) using a tissue
homogenizer. The concentration of coDbait in tissue samples
was quantified by a specific hybridization immunoassay with the
following protocol. The samples were then incubated at 95uC
for 12 min and cooled to room temperature for 20 min to form
a duplex with 300 mL of the capture probe (592/5BioTEG/
GCT GTG CCC ACA ACC -39) at 20 nM in 56 SSCT
(0.75 M NaCl, 0.075 M sodium citrate, 0.01% Tween-20). We
then added 100 mL of this mixture in duplicate to the wells of a
96-well streptavidin-coated plate (StreptaWell, Roche Applied
Science). The plate was covered and incubated for 45 min at
room temperature on an orbital shaker set at 200 rpm and
washed three times with 26 SSCT (300 mM NaCl, 30 mM
sodium citrate, 0.01% Tween-20). A detection probe (59- CAG
CAA ACA AGC CTA GA/3DigN/239) at 20 nM in 56
SSCT was added to all wells (100 mL). The plate was incubated
for 45 min at room temperature on an orbital shaker set at
200 rpm, washed three times with 26 SSCT, and incubated
45 min at room temperature with an anti-digoxigenin peroxi-
dase conjugated antibody (Roche Applied Science) diluted
1:10,000 in PBS; 0.005% Tween-20 was added to all wells
(100 mL). Detection was achieved by the addition of a TMB
substrate (100 mL) for approximately 45 min at room temper-
ature and stopped by the addition of H2SO4 0.5 M (100 mL).
The absorbance was measured using a Spectramax 340PC or
CoDbait Sensitizes Glioma to Radiotherapy in Rat
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Plus 384 microplate reader (Molecular Devices Corporation) set
at 450 nm with a 570-nm background correction. The amount
of coDbait in samples was calculated from the calibration
standards over a working range of 3.00–80.00 ng/mL using a
four-parameter logistic curve fit.
Multiparametric MR Imaging and Analysis
MRI was performed at 4.7 T (Avance III console; Bruker,
Grenoble Preclinical MRI facility). A T2-weighted (T2W)
sequence (TR/TE=4000/33 ms, voxel si-
ze = 117611761000 mm) was used to determine tumor volume
and delineate the two regions of interest (ROIs: tumor and
contralateral striatum) used for the MRI parameters. The
apparent diffusion coefficient (ADC) was mapped (TR/
TE=3000/28.6 ms, b<0 and b= 900 s/mm2, voxel si-
ze = 234623461000 mm). Vascular integrity was assessed using a
dynamic contrast- enhanced MRI approach as previously
described [21]. Briefly, multiple T1-weighted images (n = 60,
15.6 s per image) were acquired (TR/TE: 800/4.2 ms, voxel
size = 234623461000 mm). After acquisition of ten baseline
images, a bolus of Gd-DOTA (200 mmol/kg, flushed with
250 mL of saline) was administered through the tail vein. The
area under the curve of Gd-DOTA (AUCGd-DOTA) was calculated
using the 40 consecutive images subtracted from baseline. The
blood volume fraction (BVf) and vessel size index, related to the
vessel diameter (VSI) [25] were obtained from a second bolus
injection using a first-passage approach with a spiral gradient
echo, spin echo sequence (2 shots, TR/GETE/SETE:250/16.5/
50.1 ms, voxel size = 375637561000 mm) [26]. To normalize the
BVf values obtained in each animal, the BVf in the contralateral
striatum was set at 3% [22]. All parametric maps were computed
using software developed in our laboratory with Matlab (Math-
Works, Natick, MA, USA).
Two Dimensional-fluorescence Reflectance Imaging
Organ distribution of Dbait-Cy5.5 formulations was per-
formed with 2 dimensional-fluorescence reflectance imaging
(2D-FRI) system (Fluobeam) as previously described [27].
Briefly, the system is composed of 2 optical fibers 690-nm
emitting lasers (100 mW each) providing NIR excitation and a
charge-coupled device (CCD) camera to detect fluorescence
emitted by Cy5.5. This system provides continuous NIR
excitation because of the presence of a holographic lens that
produces a homogeneous lightened field (6–8 cm in diameter)
with an illumination power of 5 mW/cm2. The fluorescence
signal is collected through a high-pass filter (.720 nm) by a
digital 12-bit CCD camera that records time-lapse sequences of
images similar to a video rate (image size, 139261024; pixel
size, 6.4566.45 mm2). The fluorescent images were acquired in
5 ms and were superimposed automatically on a visible light
image obtained using an infrared-filtered white-light illuminator
(76103 lux). The brains were imaged separately, whereas all the
organs for each animal were imaged together. For the
quantification of fluorescence, expressed in mean number of
photons per pixel, the signal was corrected to the initial
quantity of injected fluorescent molecules and normalized to
1 ms. Given that cholesterol and PEI molecules are able to
locally quench the fluorescence emitted by the Cy5.5 dye when
associated with Dbait, the measurement of fluorescence was
corrected with a previously determined coefficient (Dbait = 1,
coDbait = 1.73, Dbait/PEI = 3.13) [11]. Quantification is thus
related to the same amount of injected fluorescence between
formulations.
Brain Sectioning and Histology
Coronal cryosections (10 mm thick) were cut along the entire
striatum or tumor on a microtome (Leica). Hematoxylin-erythro-
sine staining was used as previously described after fixing in
methanol/acetone (50%, v/v) and washing in tap water for 5 min
[28]. Histological observation using NIR imaging of Cy5.5-labeled
formulations of Dbait used the MacroFluo macroscope (Leica) and
the LSM710 confocal microscope (Zeiss). For the immunohistol-
ogy of p-RPA32, primary antibody was rabbit polyclonal anti-
RPA32 ser4/ser8 NB100-543 diluted 1:100 (NB 100–543, Novus
Biologicals) and secondary antibody was anti-rabbit Alexa 488
diluted 1:200 (Invitrogen).
For the immunohistology of Ki67, MBP, and ED1, the brains
were fixed in neutral buffered formalin, embedded in paraffin.
Coronal cryosections (7 mm thick) were cut along the entire tumor.
Primary antibodies were rabbit polyclonal anti-Ki67 diluted 1:500
(Ab15580, Abcam), mouse anti-ED1 diluted 1:1,000 (AbC117-
6714, AbCys), and rat anti-MBP diluted 1:100 (VMA386, AbCys).
Secondary biotin-conjugated antibodies were goat anti-rabbit
diluted 1:200 (BA-1000, Vector Laboratories), donkey anti-mouse
diluted 1:1000 (SC-2098, Santa Cruz), and rabbit anti-rat 1:500
(BA-4000, Vector Laboratories). Extradivin-conjugated peroxidase
was added 1:1000 (E-2886, Sigma) and detected with the DAB
Peroxidase Substrate Kit (SK-4100, Vector Laboratories).
Statistical Analysis
The number of rats for each experiment is given in the figure
legends. The log-rank test was used to detect statistical significance
in survival. Analysis of variance (ANOVA) was performed to
detect statistical significance in the measurement of coDbait-Cy5.5
in various organs. The Student t-test was used to detect an effect of
coDbait on the number of Ki67-positive tumor cells. Repeated
Measurement of ANOVA was performed to detect significant
effects of coDbait, RT, or combined treatments on tumor growth
and vascular properties determined with MRI. A p-value ,0.05
was considered as significant.
Results
Distribution of Dbait, Dbait/PEI, and coDbait 1 day after
Intrastriatal Injection in Normal Rats
We first investigated the distribution in normal brain tissue of
various Dbait formulations 1 day after intrastriatal injection. This
duration has been proven to be necessary for an effective
sensitizing effect of Dbait molecules to RT [10,11]. As in the
Berthault et al. study [11], the Dbait molecules were linked to
Cy5.5; the quantity of Dbait alone and coDbait was chosen to
avoid fluorescence signal saturation. Due to the solubility limit of
the Dbait molecule when associated with PEI, the maximum
achievable quantity was 10 mg of Dbait molecules. Observation of
2D-FRI on dorsal and ventral views of the brain showed a large
distribution of coDbait-Cy5.5 and Dbait-Cy5.5 within the
ipsilateral hemisphere, whereas the signal from Dbait-Cy5.5/PEI
was localized in the vicinity of the needle tract (Fig. 1A). These
observations were validated with macroscopic analysis (Fig. 1B). In
addition, we detected a high affinity of coDbait-Cy5.5 with white
matter structures such as the corpus callosum (Fig. 1B, white
arrow) and striosomes. This affinity of coDbait-Cy5.5 for
striosomes was confirmed with confocal microscopy (Fig. 1C,
white arrows). Dbait-Cy5.5 was found either concentrated along
the needle track or diffused in brain tissue with no specific
localization. A local deposit of Dbait-Cy5.5/PEI was confirmed
with little diffusion in surrounding tissue (Fig. 1C, dotted line).
CoDbait Sensitizes Glioma to Radiotherapy in Rat
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Distribution and Effect of Dbait, Dbait/PEI, and coDbait 1
day after Intratumoral Injection in RG2 Glioma-bearing
Rats
We next investigated the distribution of the various formulations
of Dbait after intratumoral injection in the RG2-glioma model
(Fig. 2). Dbait-Cy5.5 and coDbait-Cy5.5 signals were diffused
inside and outside the tumor bulk, whereas Dbait-Cy5.5/PEI was
localized near the injection track with little diffusion in surround-
ing tissue (Fig. 2A and 2B). The signal from coDbait-Cy5.5 was
also found to be intense at the tumor border and to some extent
along white matter structures in proximity of the tumor (Fig. 2A,
white arrow), which corroborates the previous observations after
intrastriatal injection (Fig. 1B).
High magnification of confocal microscopy showed coDbait-
Cy5.5 localized in the nucleus and cytoplasm, Dbait-Cy5.5 mainly
localized in the extracellular space, and a nuclear distribution for
Dbait-Cy5.5/PEI (Fig. 2B, right panel). Similar to Chen et al.
[19], we observed a selective fixation of cholesterol-coupled DNA
molecules on the white matter track and presumably on myelin
sheets. All these observations are in accordance with the recent
study of Berthault et al. [11], which explored the distribution and
toxicity of various Dbait formulations on zebrafish embryos.
The distribution in the brain determined with 2D-FRI was
similar to the distribution after intrastriatal injection (data not
shown), which validates the efficacy of CED. We also used the 2D-
FRI to quantify the florescence in various organs after isolation
(Fig. 2C). The level of Cy5.5 in the brain was significantly higher
after Dbait-Cy5.5 and coDbait-Cy5.5 injection in comparison
with control vehicle injection, whereas no statistical difference was
detected after Dbait-Cy5.5/PEI injection. A strong signal was
detected in liver, spleen, and kidney after Dbait-Cy5.5/PEI
injection but was much lower after Dbait-Cy5.5 injection and
even lower after coDbait-Cy5.5 injection. The presence of Dbait
molecules in these organs might suggest that that they could also
be found in proliferating tissues such as gut and bone marrow. We
did not measure the amount of coDbait molecule in these organs.
However, toxicity studies on rats and monkeys show that coDbait
is well tolerated with a no-observed-adverse-effect level (NOAEL)
considered to be the highest tested dose of 32 mg/animal/day
(dose range, 1612216 mg/kg/day for rats and 10.7216.2 mg/
kg/day for monkeys) (Schlegel et al., 2012, in press [29]).
Moreover, Dbait molecules mainly exert their antiproliferative
action upon irradiation [10]. As we chose a selective irradiation
protocol that targeted the animal’s head, we can assume a minor
effect of Dbait molecules in other organs than the brain.
To confirm that Dbait molecules have reached their main
target, the DSB repair enzyme DNA-PK, and to promote their
activation, we monitored the phosphorylated form of Rpa32 with
immunodetection [9]. Tumors treated by coDbait contained a
high number of p-Rpa32-positive cells (Fig. 2D), whereas very few
were detected after Dbait and Dbait/PEI injection. Comparative
studies with naked Dbait or Dbait formulated with PEI indicate
that coDbait displays good retention in brain, preferential
distribution in tumor cells, and a potent effect on DNA repair
activation.
Before choosing coDbait as the therapeutic form for evaluating
an effect of Dbait molecules on sensitizing tumor to RT in animal
models, we quantified coDbait concentration in various brain
areas 1 day after intratumoral injection. Rats bearing a 14-day-old
tumor received an intratumoral injection by CED of coDbait
(400 mg, n = 3). Brain samples were isolated and homogenized and
Dbait content was measured. For this study, we used a new
technology based on hybridization combined with ELISA
Figure 1. Distribution in normal brain of various formulations of Dbait, 1 day after intrastriatal injection. Rats received an intracranial
injection by CED of one Dbait formulation coupled with the Cy5.5 near-infrared dye (Dbait-Cy5.5:100 mg, n = 2; Dbait-Cy5.5/PEI: 10 mg, n = 2; coDbait-
Cy5.5:100 mg, n = 2). (A) Distribution in whole brain (dorsal and ventral views) was determined with 2D-FRI. Intensity scale was normalized within each
group. (B) Distribution in brain sections determined with macroscopy. The white arrows show a local accumulation of coDbait in corpus callosum. (C)
Distribution at the cellular level determined with confocal microscopy. The dotted line in the Dbait/PEI panel delineates the local deposit near the
needle track and the white arrows show a local accumulation of coDbait in striosomes determined with light microscopy. Scale bar = 100 mm.
doi:10.1371/journal.pone.0040567.g001
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Figure 2. Distribution, quantification, and effect of various formulations of Dbait 1 day after intratumoral injection in RG2 glioma.
(A–D) Rats bearing a 14-day-old tumor received an intratumoral injection by CED of one Dbait formulation coupled with the near-infrared dye Cy5.5
(Dbait-Cy5.5:100 mg, n = 4; Dbait-Cy5.5/PEI: 10 mg, n = 4; coDbait-Cy5.5:100 mg, n = 4). Intratumoral injection was guided with anatomic MRI
performed 1 day prior to injection. Images from one animal representative of each group are presented. (A) Anatomic localization of RG2 tumor with
T2W MRI and corresponding distribution of Dbait formulations in brain sections determined with macroscopy. The white arrows show a local
accumulation of coDbait in corpus callosum. (B) Distribution of Cy5.5 at the cellular level determined with confocal microscopy; left panel scale
bar = 100 mm and right panel scale bar = 6.7 mm. The dotted line in the Dbait/PEI panel delineates the local deposit near the needle track. (C)
Fluorescence measurement of Cy5.5 in several organs determined with 2D-FRI and compensated for the quantity of fluorescent molecules injected.
Value expressed as light unit (LU) per ms and pixel. ANOVA, Dbait formulations versus vehicle, *: p,0.05. Mean 6 SD. (D) Immunodetection of p-
Rpa32, scale bar = 20 mm.
doi:10.1371/journal.pone.0040567.g002
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detection (see Material and Methods) that specifically quantifies
coDbait molecules with the complete DNA sequence. As
previously observed by fluorescence analysis, the concentration
of coDbait was very low in the contralateral (0.860.8 mg/g of
tissue) and ipsilateral (30.5621.8 mg/g of tissue) brain hemispheres
in comparison with the level of coDbait found in tumor bulk
(305.56277.9 mg/g of tissue). Note that coDbait level achieved its
maximum in the peritumoral area (673.66213.0 mg/g of tissue).
Tolerance to coDbait in Normal Brain
We controlled animal and tissue tolerance to coDbait 7 and 14
days after intrastriatal injection. For this purpose, we used 200 and
500 mg of coDbait in order to determine tolerance with a large
quantity of Dbait molecules. The animals showed no sign of
behavioral deficit, based on clinical observation, and had a normal
weight curve. Histological observations 7 and 14 days after
injection of 200 and 500 mg of coDbait were similar and confirmed
that the structure of brain parenchyma is preserved (Fig. 3A). We
observed a minor loosening of tissue that might be due to coDbait
binding to white matter tracts, as seen in Fig. 1B and 2A, and/or
to the mode of injection given that a similar aspect was seen when
no solution or only the vehicle was injected (data not shown).
The Experimental Setup Consisting of 2 coDbait
Injections Each Followed by a 6-Gy Irradiation is well
Tolerated in Normal Rats
Our main goal is to amplify the positive effect of RT and
simultaneously reduce the deleterious effects on surrounding
tissue. Therefore, we combined injection of coDait 1 day before
each RT treatment (two treatment cycles over 1 week) to minimize
the invasiveness of the procedure with repeated anesthesia. For
this preliminary experiment, we chose a well-tolerated quantity of
coDbait: 100 mg for each injection. Two irradiation protocols were
tested on normal rats, consisting of (i) a 266-Gy RT: one 6-Gy
session after each coDbait injection (n= 12 rats) or (ii) a 465-Gy
RT: two consecutive 5-Gy sessions over 1 day after each coDbait
injection (n= 12 rats). For each protocol, three treatment
combinations were tested: coDbait, vehicle+RT, and coD-
bait+RT. Independently of the coDbait injection, most animals
that received the 465-Gy RT lost more than 20% of their normal
weight, suggesting low tolerance of the irradiation protocol, which
forced us to abort the experiment. This was probably due to the
repeated anesthesia and irradiation. For the groups that were
exposed to the 266-Gy RT, the animals’ weight decreased slightly
(less than 10%) during treatment and increased after its
completion (data not shown).
For the 266-Gy RT protocol, we also looked at the effect of
treatment on brain tissue properties assessed by multiparametric
MRI before (D-1) treatment, 2 days (D9) and 13 days (D20) after
treatment completion (Fig. 3B). Compared to D-1, no effect was
detected in the contralateral striatum. Some trends were observed
at D9 on ADC, BVf, and AUCGd-DOTA in the injected
hemisphere; however, none of them was statistically significant
and they returned to the baseline level on D20. All these data
indicate that the 266-Gy RT protocol was well tolerated and can
be applied to glioma-bearing rats.
coDbait with RT Increases the Animals’ Lifespan by
Reducing Tumor Progression without Impacting Tumor
Vascularization
The experimental protocol used to assess the radiosensitizing
effect of coDbait is presented in Figure 4A. Two coDbait
injections, 400 mg each, were performed at 1-week intervals.
Figure 3. Long-term effect of coDbait in normal brain. (A)
Hematoxylin-eosin stained sections of normal brain, 14 days after
injection in striatum of coDbait (500 mg). Rats received an intracranial
injection by CED of coDbait (200 and 500 mg, n = 2 each). Rats were
euthanized 7 or 14 days after injection and brain sections were
observed with histology after hematoxylin-erythrosine histology.
Contra: contralateral hemisphere, ipsi: ipsilateral injected hemisphere.
Dotted rectangle represents the area of the 610 magnification. (B)
Effect of coDbait and RT in normal brain on the injected and
contralateral striatum properties determined with multiparametric
MRI. Treatment was organized as follows: D0: intratumoral injection
by CED of coDbait (100 mg) or vehicle (glucose 5%), D1:6-Gy irradiation,
D6: same as D0, D7: same as D1, see Fig. 5A for a more concise view of
the experimental set-up. Three combinations of treatments were
administered: coDbait, vehicle+RT, and coDbait+RT (n = 3 each). The
animals’ weight was monitored. Multiparametric MRI was performed
before (D-1) treatment, 2 days (D9) and 13 days (D20) after treatment
completion. ADC: apparent diffusion coefficient, AUCGd-DOTA: area under
curve of Gd-DOTA extravasation, BVf: blood volume fraction. Mean BVf
in the contralateral striatum was set at 3% for normalization purposes.
Mean 6 SD.
doi:10.1371/journal.pone.0040567.g003
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One day after each coDbait injection, a 6-Gy irradiation was
applied to the whole brain. The quantity of coDbait molecules was
chosen slightly lower than the maximal dose tested in the tolerance
study (500 mg) to minimize the potential effect of two repeated
injections.
The good tolerance of animals to coDbait treatment was
confirmed with animal survival that did not differ between
untreated animals and animals that received coDbait (Fig. 4B). In
contrast, Kaplan-Meier survival analysis revealed a statistically
significant prolongation of animal survival in the vehicle+RT
group (median, 22 days) compared with the vehicle and coDbait
groups (median, 18 versus 17 days, respectively). This prolonga-
tion was significantly increased in the coDbait+RT group (median,
24 days) in comparison with the vehicle+RT group.
To confirm that survival extension was the consequence of
better tumor growth control by the combined treatment, we
monitored tumor progression, as shown in Figure 4C, with T2W
anatomic MRI before (D21), during treatment (D5), and at three
time points after the end of treatment (D9, D11, and D13). At
early times, RM-ANOVA between D-1 and D9 revealed a
significant reduction in tumor growth induced by RT, but no
additional effect of coDbait was detected. However, after D9, RM-
ANOVA revealed that the tumor progression was statistically
delayed with coDbait+RT treatment in comparison with vehi-
cle+RT treatment. Consistent with this finding, histological
analysis of the tumors confirmed that the amount of proliferating
Ki67-positive cells was significantly reduced on D9 after
coDbait+RT treatment as compared to single RT (Fig. 4D).
Interestingly, this difference decreased at D13 as tumors started to
grow again (D13, Fig. 4C).
Given that RT is known to promote changes in tumor
vasculature, we raised the question of whether coDbait injection
associated with RT might additionally modify the tumor
microenvironment with an effect on vascularization [30–32]. For
this purpose, we applied a multiparametric MRI analysis to
monitor the vascularization properties of the tumor and the
contralateral striatum before and 2 days after the end of treatment
(Fig. 5). No differences between treatments were observed in the
Figure 4. Effect of treatments on animal survival, tumor
growth, and cell proliferation. (A) Experimental design, animals
(n = 68) were implanted with RG2 glioma 14 days prior to treatment.
Treatment was organized as follows: D0: intratumoral injection of
coDbait (400 mg) or vehicle (glucose 5%), D1:6-Gy irradiation, D6: same
as D0, D7: same as D1. Four combinations of treatments were
performed: vehicle, coDbait, vehicle+RT, and coDbait+RT. The animals
were euthanized at the onset of neurologic signs [42]. The day of
euthanasia was recorded to monitor the effect of treatments on
survival. MRI was performed as follows: D-1: multiparametric MRI and
group randomization based on tumor volume, D5: anatomic MRI, D9:
multiparametric MRI, D11 and D13: anatomic MRI. This experiment was
carried out in two studies that reproduced a similar tumor growth
pattern for each group so that the data could be pooled. The first study
was done to assess animal survival, whereas the second one was done
to assess tumor progression after D9 and to perform the histological
analysis on brain tissues isolated at D11 and D13. (B) Kaplan-Meier
survival plot. The horizontal bar depicts treatment duration. Log rank
test, £: p,0.05 (vehicle n = 9; coDbait n = 12; vehicle+RT n= 10;
coDbait+RT n=13). (C) Tumor volume measured with T2W MRI before
(D-1; vehicle n = 12; coDbait n = 6; vehicle+RT n= 16; coDbait+RT n= 17),
during (D5; vehicle n= 12; coDbait n = 6; vehicle+RT n= 16; coDbait+RT
n = 17), and after treatment (D9: vehicle n = 12; coDbait n = 6;
vehicle+RT n=16; coDbait+RT n= 17; D11 and D13: vehicle n= 5;
vehicle+RT n= 7; coDbait+RT n= 14). The horizontal black bar depicts
treatment duration. RM-ANOVA, $: effect of RT between D-1 and D5 or
D-1 and D9, p,0.05, *: effect of coDbait with RT between D-1 and D11
or D-1 and D13, p,0.05. (D) Percentage of Ki67-positive cells in tumor
bulk at D9 (vehicle+RT n=6; coDbait+RT n= 4) and D13 (vehicle+RT
n= 8; coDbait+RT n= 4). Student t-test, #: effect of coDbait with RT.
Mean 6 SD.
doi:10.1371/journal.pone.0040567.g004
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contralateral striatum for all parameters analyzed. For the vehicle
group, all parameters were increased in the tumor between D-1
and D9. RT prevented the augmentation of BVf and VSI found in
the vehicle group, whereas it increased the augmentation of ADC
in the tumor. The augmentation of AUCGd-DOTA, a measurement
that is related to vessel permeability, remained similar for each
treatment. Even though a later effect after the end of treatment
cannot be excluded, no deleterious or synergic effect of coDbait
injection with RT on tumor vasculature was detected 2 days after
the end of treatment (D9).
coDbait with RT Increases ED1-positive Macrophage
Infiltration and Destabilizes MBP-Positive Myelin
Elements in the Tumor Microenvironment
Two days after treatment completion (D9), immunohistological
analysis of ED1-positive macrophages showed a limited infiltration
at the tumor border after RT alone (Fig. 6A), whereas many ED1-
positive macrophages are detected after coDbait with RT
treatment in a wide zone surrounding the tumor. This infiltration
decreased on D13. Immunohistological analysis of MBP-positive
myelin elements showed that RT alone preserved the structure of
striosomes around the tumor (Fig. 6B). At D9, coDbait with RT
induced a substantial loss of MBP labeling surrounding the tumor,
presumably due to a destabilization of striosomes (Fig. 6B, white
arrow). This effect was increased at D13 when striosomes were
barely detected in some parts around the tumor.
These observations can be interpreted as a deleterious effect of
coDbait with RT on the tumor microenvironment, associated with
an increased inflammation accompanied by destabilization of
striosomes. This might help reduce the invasion of tumor cells to
the surrounding tissues, which is in part assisted by the white
matter tract [33].
Discussion
A therapeutic protocol was designed with two coDbait
injections, each followed by a 6-Gy irradiation. CoDbait with
RT increased the survival of rats principally by slowing tumor
growth, whereas the tumor vasculature remained similar to that of
control-irradiated tumors. Here, two cycles of treatment, each
consisting of one coDbait injection followed by one irradiation of
the head, improved the survival of rats bearing an RG2-glioma.
These results are in good agreement with previous studies
conducted on human melanoma tumor subcutaneous xenografts
[10,11]. In our study, RT delayed tumor progression at D9, i.e., 2
days after the end of treatment. Interestingly, the effect of coDbait
in synergy with RT was observed later, extending tumor growth
control to D11 and D13, i.e., 4 and 6 days after the end of
treatment. Despite the decrease in cell proliferation at D9 detected
with Ki67 labeling, tumor size was similar between both RT
groups and the coDbait with RT did not promote changes in the
tumor volume per se. Such an apparent lack of treatment effect at
an early time after treatment has already been well documented
clinically by the diagnosis of ‘‘pseudo-progression’’ in patients who
respond to treatment [34–36].
The multiparametric MRI measurement was used to evaluate
whether the synergic effect of coDbait with RT on tumor survival
might result from an additional impact on tumor vasculature. BVf,
vessel integrity determined with AUCGd-DOTA and VSI, a value
related to vessel diameter, were increased along the natural course
of tumor development. At D9, RT reduced BVf and VSI but not
AUCGd-DOTA, in agreement with the observed delay in tumor
progression. We failed to detect any effects of coDbait or coDbait
with RT on tumor vasculature. This is in good agreement with a
Figure 5. Effect of treatments on tumor properties determined
by multiparametric MRI before and after treatment. Multi-
parametric MRI was performed as given in Fig. 5A. ADC: apparent
diffusion coefficient (vehicle n = 6; coDbait n = 6; vehicle+RT n= 9;
coDbait+RT n = 10), AUCGd-DOTA: area under curve of Gd-DOTA
extravasation (vehicle n = 6; coDbait n = 6; vehicle+RT n= 9; coDbait+RT
n= 10). BVf: blood volume fraction. Mean BVf in the contralateral
striatum was set at 3% for normalization purposes (vehicle n= 6;
coDbait n = 6; vehicle+RT n= 8; coDbait+RT n= 10). VSI: vessel size index
(vehicle n = 3; coDbait n = 4; vehicle+RT n= 8; coDbait+RT n= 10). RM-
ANOVA, $: effect of irradiation between D-1 and D9, p,0.05. Mean 6
SD.
doi:10.1371/journal.pone.0040567.g005
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Figure 6. Effect of treatments on myelin sheets and macrophage infiltration before (D-1) and after (D9) treatment. A)
Immunodetection of MBP-positive myelin elements. B) Immunodetection of ED1-positive cells. Representative images are presented. D9 (vehicle+RT
n= 6; coDbait+RT n=4) and D13 (vehicle+RT n= 8; coDbait+RT n=4). Dotted rectangle represents the area of the62 magnification; cc = corpus
callosum, str = striatum, t = tumor bulk. White arrows in B) show striosomes.62 images, scale bar = 1 mm;610 images, scale bar = 200 mm.
doi:10.1371/journal.pone.0040567.g006
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selective radiosensitzing effect of coDbait strictly on tumor cell
proliferation. This result suggests that one additional treatment
with antiangiogenic or antivascular drugs that target the tumor
vasculature could be used to increase the beneficial effect of
coDbait with RT. Such combined therapies are already being
investigated in clinical studies [37,38].
Most previous studies have been conducted on nude mice
xenografted with human tumors. Therefore, immune and
inflammatory response was not addressed in these studies. Here,
for the first time we have described an interesting observation that
coDbait with RT increases inflammation and destabilizes the
microenvironment. These properties could play an important role
in recurrence of glioma.
We show that coDbait amplified the effect of RT by impairing
tumor cell proliferation, as seen at D9. The tumor size reduction
was no longer detected at D13, i.e., 6 days after the end of
treatment. A previous study reported by Quanz et al. [10] showed
that upon irradiation, the Dbait molecule exerts a beneficial dose-
dependent effect on the life span of mice with a xenografted model
of head and neck squamous cell carcinoma. Given the observa-
tions of a dose-dependent effect of Dbait molecules, the injection
with a larger amount of Dbait molecules would presumably
increase the beneficial effect of coDbait with irradiation.
CED induces a pressure-driven flow allowing a homogenous
distribution of drugs over large volumes [39]. In our study,
coDbait after CED injection does not cover the entire tumor mass.
This can be attributed to the high interstitial pressure present in
this tumor type, which provokes fluid flow from the tumor to
surrounding tissue [40]. The injection volume, i.e., 10 mL, might
be insufficient to cover the entire tumor volume. The injected
volume might be increased but with the limitations of an extended
injection time, limiting its clinical use, where tumors are larger
[39].
One alternative to the CED could be the use of an implanted
delivery system such as an osmotic pump that can deliver a higher
volume of molecules at a constant rate over a long period. This
strategy has already shown promising results in the context of
glioma for intratumoral delivery of carboplatin [41] and might be
suitable in association with a highly fractionated RT that is
commonly used in the clinical setting. The local delivery strategy is
of great interest because this can be combined in the clinic with
resection therapy followed by RT or chemotherapy, thereby
causing no further damage from drug delivery [39]. A preliminary
study from our group showed that coDbait molecules accumulated
in tumor after intravenous injection (data not shown). However,
this type of coDbait administration needs further investigation
regarding the maximum achievable doses in tumor and systemic
toxicity but is highly promising for clinical purposes.
CoDbait molecules have no deleterious effect on healthy brain
tissues. The intratumoral injection of coDbait prior to RT
improves the survival of rats and reduces tumor volume by
amplifying the effect of RT without altering tumor vasculature.
CoDbait is therefore a promising molecular therapy to sensitize
glioma to RT.
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